Stock 4591 RIBOMIC INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Ribomic Inc.

Equities

4591

JP3974850004

Delayed Japan Exchange
Other stock markets
 06:14:42 16/05/2024 BST 		5-day change 1st Jan Change
84 JPY -1.18% Intraday chart for Ribomic Inc. 0.00% -22.22%
03-07 Ribomic Inc. announced that it has received ¥4.192212 million in funding from SMBC Nikko Securities Inc. CI
02-20 Ribomic Inc. announced that it expects to receive ¥4.192212 million in funding from SMBC Nikko Securities Inc. CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ribomic Inc. Reports Earnings Results for the Nine Months Ended December 31, 2023
Ribomic Enters Into Drug Research Collaboration with Ajinomoto
RIBOMIC Inc. and Ajinomoto Co., Inc. Announce Joint Research Agreement
RIBOMIC Phase I and II Data Published in the Eye
Ribomic Inc. Reports Earnings Results for the Half Year Ended September 30, 2023
Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2024
Ribomic Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023
Ribomic Inc. Reports Earnings Results for the Full Year Ended March 31, 2023
Ribomic Inc. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024
Ribomic Inc. Reports Earnings Results for the Full Year Ended March 31, 2023
RIBOMIC, Inc. Announces Start of Administration of RBM-007, Achondroplasia Investigational Drug, to the First Patient in the Early Phase II Study in Japan
Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2023
Ribomic Inc. Reports Earnings Results for the Nine Months Ended December 31, 2022
RIBOMIC Announces MOU to Establish Joint Venture for Development of RBM-007 in China
Japan Stocks Buried under Persistent US Monetary Tightening; Eisai Tanks 6% as Alzheimer's Trial Death Count Rises to Two
Ribomic Inc. Announces the First Case Registration of Observational Study for RBM-007 Early Phase2 Development Project in Achondroplasia Patients
Ribomic Inc. Reports Earnings Results for the Half Year Ended September 30, 2022
Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2023
Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2023
RIBOMIC Announces Publication of anti-TGF-ß1 Aptamer Data Demonstrating Enhancement of anti-cancer Drug Efficacy
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4591 Stock
  4. News Ribomic Inc.
  5. Other languages